Evidence map›Paper›PMID 29610863›Full record

ArticleAnnals of internal medicine2018

Evaluating Vaccination Strategies for Zika Virus in the Americas.

David P Durham, Meagan C Fitzpatrick, Martial L Ndeffo-Mbah, Alyssa S Parpia, Nelson L Michael, Alison P Galvani

Open access · greenAbstract read
In one paragraph

Article in Annals of internal medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

David P DurhamCenter for Infectious Disease Modeling and Analysis, Yale School of Public Health, New Haven, Connecticut (D.P.D., M.L.N., A.S.P., A.P.G.).
Meagan C FitzpatrickCenter for Infectious Disease Modeling and Analysis, Yale School of Public Health, New Haven, Connecticut, and Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland (M.C.F.).
Martial L Ndeffo-MbahCenter for Infectious Disease Modeling and Analysis, Yale School of Public Health, New Haven, Connecticut (D.P.D., M.L.N., A.S.P., A.P.G.).
Alyssa S ParpiaCenter for Infectious Disease Modeling and Analysis, Yale School of Public Health, New Haven, Connecticut (D.P.D., M.L.N., A.S.P., A.P.G.).
Nelson L MichaelU.S. Military HIV Research Program, Walter Reed Army Institute of Research, Bethesda, Maryland (N.L.M.).
Alison P GalvaniCenter for Infectious Disease Modeling and Analysis, Yale School of Public Health, New Haven, Connecticut (D.P.D., M.L.N., A.S.P., A.P.G.).
Yale University · USUniversity of Maryland, Baltimore · USWalter Reed Army Institute of Research · US

Funding

FELLOWSHIP TRAINING PROGRAM IN VACCINOLOGYT32AI007524 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI Marcelo B. Sztein · 1997 to 2026
$6.4M
Impacts of Individual and Social Behavior on Influenza Dynamics and ControlU01GM087719 · NIGMS · YALE UNIVERSITY · PI GALVANI, ALISON P, MEYERS, LAUREN ANCEL · 2009 to 2018
$6.3M
Accelerating viral outbreak detection in US cities using mechanistic models, machine learning and diverse geospatial dataR01AI151176 · NIAID · YALE UNIVERSITY · PI GALVANI, ALISON P, MEYERS, LAUREN ANCEL · 2020 to 2024
$3.9M
YALE BIOMEDICAL SUPERCOMPUTER: NEUROSCIENCES10RR019895 · NCRR · YALE UNIVERSITY · PI WILLIAMS, KENNETH ROBERT · 2004 to 2004
$1.6M
Evaluating the social influences that impact vaccination decisionsU01GM105627 · NIGMS · YALE UNIVERSITY · PI GALVANI, ALISON P · 2013 to 2017
$1.6M
High Performance Computing Instrumentation for Yale University Biomedical HPC CenS10RR029676 · NCRR · YALE UNIVERSITY · PI BJORNSON, ROBERT DEAN · 2011 to 2011
$588k
NCRR NIH HHS S10 RR019895NCRR NIH HHS S10 RR029676NIAID NIH HHS R01 AI151176NIAID NIH HHS T32 AI007524NIGMS NIH HHS U01 GM087719NIGMS NIH HHS U01 GM105627
6 · The paper itself

Abstract

Background: Mosquito-borne and sexually transmitted Zika virus has become widespread across Central and South America and the Caribbean. Many Zika vaccine candidates are under active development. Objective: To quantify the effect of Zika vaccine prioritization of females aged 9 to 49 years, followed by males aged 9 to 49 years, on incidence of prenatal Zika infections. Design: A compartmental model of Zika transmission between mosquitoes and humans was developed and calibrated to empirical estimates of country-specific mosquito density. Mosquitoes were stratified into susceptible, exposed, and infected groups; humans were stratified into susceptible, exposed, infected, recovered, and vaccinated groups. Age-specific fertility rates, Zika sexual transmission, and country-specific demographics were incorporated. Setting: 34 countries and territories in the Americas with documented Zika outbreaks. Target Population: Males and females aged 9 to 49 years. Intervention: Age- and sex-targeted immunization using a Zika vaccine with 75% efficacy. Measurements: Annual prenatal Zika infections. Results: For a base-case vaccine efficacy of 75% and vaccination coverage of 90%, immunizing females aged 9 to 49 years (the World Health Organization target population) would reduce the incidence of prenatal infections by at least 94%, depending on the country-specific Zika attack rate. In regions where an outbreak is not expected for at least 10 years, vaccination of women aged 15 to 29 years is more efficient than that of women aged 30 years or older. Limitation: Population-level modeling may not capture all local and neighborhood-level heterogeneity in mosquito abundance or Zika incidence. Conclusion: A Zika vaccine of moderate to high efficacy may virtually eliminate prenatal infections through a combination of direct protection and transmission reduction. Efficiency of age-specific targeting of Zika vaccination depends on the timing of future outbreaks. Primary Funding Source: National Institutes of Health.

Indexed as

AdolescentAdultAge FactorsAmericasChildFemaleHumansImmunity, HerdIncidenceInfectious Disease Transmission, VerticalMaleMass VaccinationMiddle AgedMosquito VectorsPopulation DensityPregnancy

Identifiers

PMID29610863
PMCPMC5955609
OpenAlexW2795383549

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.